Erasca (ERAS) Cash & Equivalents (2020 - 2026)
Erasca posted quarterly Cash & Equivalents of $47.3 million for Q1 2026, down 32.95% year-on-year from $70.5 million in Q1 2025, and down 35.97% on a QoQ basis from $73.8 million in Q4 2025.
Erasca (ERAS) has 7 years of Cash & Equivalents data on file, last reported at $47.3 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Equivalents fell 32.95% year-over-year to $47.3 million; the trailing twelve-month figure through Mar 2026 stood at $47.3 million (down 32.95% YoY), and the FY2025 full-year result was $73.8 million, up 8.95% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $47.3 million, down from $73.8 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $333.3 million in Q1 2022 and bottomed at $47.3 million in Q1 2026.
- The 5-year median for Cash & Equivalents is $112.9 million (2023), against an average of $146.1 million.
- The widest annual swing landed in 2022, when Cash & Equivalents jumped 96.1%; it then plunged 67.25% in 2023.
- A 5-year view of Cash & Equivalents shows it stood at $284.2 million in 2022, then slumped by 67.25% to $93.1 million in 2023, then retreated by 27.22% to $67.7 million in 2024, then rose by 8.95% to $73.8 million in 2025, then plunged by 35.97% to $47.3 million in 2026.
- The last three Cash & Equivalents figures came in at $47.3 million (Q1 2026), $73.8 million (Q4 2025), and $70.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 47.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.26 Mn |
| Dec 31, 2025 | 73.81 Mn |
| Sep 30, 2025 | 70.23 Mn |
| Jun 30, 2025 | 66.14 Mn |
| Mar 31, 2025 | 70.48 Mn |
| Dec 31, 2024 | 67.74 Mn |
| Sep 30, 2024 | 68.89 Mn |
| Jun 30, 2024 | 172.80 Mn |
| Mar 31, 2024 | 172.80 Mn |
| Dec 31, 2023 | 93.08 Mn |
| Sep 30, 2023 | 112.86 Mn |
| Jun 30, 2023 | 138.79 Mn |
| Mar 31, 2023 | 272.76 Mn |
| Dec 31, 2022 | 284.22 Mn |
| Sep 30, 2022 | 219.26 Mn |
| Jun 30, 2022 | 219.26 Mn |
| Mar 31, 2022 | 333.35 Mn |
| Dec 31, 2021 | 360.49 Mn |
| Sep 30, 2021 | 445.81 Mn |
| Jun 30, 2021 | 156.40 Mn |
| Mar 31, 2021 | 169.99 Mn |
| Dec 31, 2020 | 65.38 Mn |
| Sep 30, 2020 | 62.02 Mn |
| Jun 30, 2020 | 104.34 Mn |